Cogent Biosciences (COGT) Projected to Post Earnings on Monday

Cogent Biosciences (NASDAQ:COGT) is expected to be releasing its earnings data before the market opens on Monday, February 24th. Analysts expect Cogent Biosciences to post earnings of ($0.59) per share for the quarter.

Cogent Biosciences Trading Down 1.1 %

COGT stock opened at $8.00 on Friday. Cogent Biosciences has a twelve month low of $5.73 and a twelve month high of $12.61. The company’s 50 day moving average is $8.25 and its two-hundred day moving average is $9.59. The stock has a market cap of $883.68 million, a P/E ratio of -3.23 and a beta of 1.77.

Analyst Ratings Changes

COGT has been the topic of a number of research reports. HC Wainwright lowered their target price on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Wedbush restated a “neutral” rating and set a $11.00 target price on shares of Cogent Biosciences in a research report on Monday, January 13th. Needham & Company LLC lowered shares of Cogent Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. raised their target price on shares of Cogent Biosciences from $19.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Cogent Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $14.33.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.